Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)
- Charles J. Ryan
- , Walter M. Stadler
- , Bruce Roth
- , Douglass Hutcheon
- , Shauna Conry
- , Thomas Puchalski
- , Charles Morris
- , Eric J. Small
Research output: Contribution to journal › Article › peer-review
71
Link opens in a new tab
Scopus
citations